دورية أكاديمية

Adjuvant nivolumab plus ipilimumab vs placebo for patients with localized renal cell carcinoma at high risk of relapse after nephrectomy: Subgroup analyses from the phase 3 CheckMate 914 (part A) trial.

التفاصيل البيبلوغرافية
العنوان: Adjuvant nivolumab plus ipilimumab vs placebo for patients with localized renal cell carcinoma at high risk of relapse after nephrectomy: Subgroup analyses from the phase 3 CheckMate 914 (part A) trial.
المؤلفون: Motzer, Robert J., Russo, Paul, Grünwald, Viktor, Tomita, Yoshihiko, Barthélémy, Philippe, Goh, Jeffrey C., Cutuli, Hernán Javier, Simsek, Burcin, Spiridigliozzi, Julia, Chudnovsky, Aleksander, Bex, Axel
المصدر: Journal of Clinical Oncology; 2023 Supplement 16, Vol. 41, p4506-4506, 1p
قاعدة البيانات: Supplemental Index
الوصف
تدمد:0732183X
DOI:10.1200/JCO.2023.41.16_suppl.4506